CATO SMS Acquires Nuventra to Add Clinical Pharmacology Capabilities
May 26, 2021
CATO SMS has acquired Nuventra, a Durham, North Carolina–based clinical pharmacology science and services provider, to expand its drug development offering into clinical pharmacology, pharmacometrics and model‑informed drug development. The deal brings Nuventra's PK/PD, population PK/PD and biosimulation expertise into CATO SMS's existing regulatory, biostatistics and clinical trial services to reduce development risk, cost and timelines for biopharmaceutical clients.
- Buyers
- CATO SMS
- Targets
- Nuventra, Inc.
- Industry
- Healthcare Services
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Cato Research Merges With SMS-oncology to Form CATO SMS
October 28, 2019
Healthcare Services
Cato Research, LLC has merged with Specialized Medical Services-oncology BV (SMS-oncology); the combined company will transition to the name CATO SMS. The deal expands Cato's oncology and regulatory capabilities and broadens the combined company's presence across Europe and North America; financial terms were not disclosed.
-
CATO SMS Acquires Array Biostatistics
September 15, 2020
Healthcare Services
CATO SMS has acquired Wilmington, North Carolina–based Array Biostatistics to expand its biostatistical consulting, analysis and statistical programming capabilities. The acquisition is an add-on to the PE-backed CATO SMS platform and aims to broaden CATO SMS’ biometrics offering for small and emerging biopharmaceutical clients, particularly in oncology, rare/orphan indications and cell & gene therapy.
-
Sygnature Discovery Acquires NuChem Sciences
August 1, 2023
Biotechnology
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
-
Sterling Pharma Solutions Acquires CiVentiChem US Facility in Cary, North Carolina
April 3, 2019
Pharmaceuticals
UK-based CDMO Sterling Pharma Solutions, a portfolio company of GHO Capital, has acquired the CiVentiChem US facility in Cary, North Carolina to establish a local presence for its North American clients and expand its chemistry development and kilo-scale cGMP capabilities. The acquisition supports Sterling’s strategy to build a global chemistry services business and follows GHO Capital’s majority investment in Sterling earlier this year.
-
Novartis Acquires Cadent Therapeutics
December 17, 2020
Biotechnology
Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts–based clinical‑stage neuroscience company, adding two clinical‑stage programs for schizophrenia and movement disorders plus the buyout of MIJ821 milestones/royalties. The deal (reported up to $770 million including milestones) strengthens Novartis' neuropsychiatry portfolio and is expected to close in Q1 2021 subject to customary conditions.
-
NAMSA Acquires Syntactx
January 5, 2021
Healthcare Services
NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.